What is in development for Glioma & glioblastoma, drawn from the whole corpus: 148 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Glioblastoma: no systemic drug has beaten the 2005 standard; getting drugs across the blood-brain barrier is the crux.
Glioblastoma's standard has not changed since 2005: every phase 3systemic agent since temozolomide has failed, so median survival has not moved in 20 years.
MGMT-unmethylated glioblastoma (~60%) gains almost nothing from chemotherapy and has no approved alternative.
Blood-brain barrier and diffuse infiltration limit delivery and resection; imaging cannot distinguish progression from pseudoprogression reliably.
Immunotherapy failure: low TMB, T-cell exclusion, dexamethasone, and treatment-induced lymphopenia; neoadjuvant approaches are the only signal.
Antigen heterogeneity and loss (EGFRvIII, IL13Rα2) undermine single-target vaccines, ADCs, and CAR-T.
Paediatric tumours (DIPG) have one approved drug with 22% response; durable control remains out of reach.
Trial design: single-arm and external-control comparisons (DCVax-L, historical vaccine data) have repeatedly misled the field.
What changed
48
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.